Univec, Inc. (UNVC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $5.05M is the value of all shares combined. Beta 1.26: the stock has moved about 26% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerUnivec, Inc. (UNVC) trades at $0.002. Univec, Inc. produces and markets medical products, primarily auto-disable and safety syringes, in the United States and internationally. The company also assists pharmaceutical companies with marketing and fulfillment services. Market cap: $5.05M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for UNVC: UNVC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UNVC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
UNVC: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Univec, Inc. (UNVC) Healthcare & Pipeline Overview
Univec, Inc. focuses on the development and distribution of specialized medical devices, including safety syringes, catering to healthcare facilities and governments, while also providing marketing support to pharmaceutical companies. The company operates within the competitive specialty and generic drug manufacturing sector.
What Is the Investment Thesis for UNVC?
Univec, Inc. presents a speculative investment opportunity within the niche market of safety syringes and medical product distribution. The company's focus on auto-disable and safety syringes addresses a critical need in healthcare, particularly in developing countries. However, with a negative profit margin of -2298.5% and a small market capitalization of $5.05M, the company faces significant financial challenges. Growth catalysts include potential contracts with governments for vaccine distribution and expansion of its pharmaceutical marketing services. Key risks include intense competition, limited financial resources, and the ability to scale operations effectively. Investors should carefully consider the high-risk nature of this OTC-listed stock.
Based on FMP financials and quantitative analysis
UNVC Key Highlights
Market capitalization of $5.05M, indicating a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -4.91, reflecting current unprofitability but potential for future earnings growth.
- Profit Margin of -2298.5%, highlighting substantial operational inefficiencies or significant one-time expenses.
- Gross Margin of -6.9%, indicating that the cost of goods sold exceeds revenue, requiring immediate attention to pricing and cost management.
- Beta of 1.26, suggesting that the stock is more volatile than the market, potentially offering higher returns but also greater risk.
Who Are UNVC's Competitors?
UNVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BGXX Bright Green Corporation | $0.04 | +5328.57% | $7.26M | — |
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are UNVC's Key Strengths?
Specialized product line of safety syringes.
- Proprietary online system for drug sample management.
- Potential for growth in developing countries.
- Experience in supplying to government healthcare programs.
What Are UNVC's Weaknesses?
Small market capitalization and limited financial resources.
- Negative profit margin and gross margin.
- Dependence on a limited number of products and markets.
- Small number of employees.
What Could Drive UNVC Stock Higher?
Potential contracts with governments for vaccine distribution programs.
- Expansion of pharmaceutical marketing services to new clients.
- Development and launch of new safety syringe technologies.
- Strategic partnerships or acquisitions to expand product portfolio and market reach.
What Are the Key Risks for UNVC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger medical device manufacturers.
- Stringent regulatory requirements and compliance costs.
- Fluctuations in currency exchange rates.
- Product liability claims.
- Limited financial resources and negative profitability.
What Are the Growth Opportunities for UNVC?
- Expanding Distribution in Developing Countries: Univec can capitalize on the growing demand for safety syringes in developing countries, driven by increasing awareness of healthcare safety and government initiatives to prevent needle stick injuries. Success hinges on Univec's ability to navigate regulatory hurdles and establish reliable distribution networks.
- Enhancing Pharmaceutical Marketing Services: Univec's online system for marketing, fulfillment, and tracking drug samples offers a valuable service to pharmaceutical companies. By expanding the platform's capabilities and integrating advanced analytics, Univec can attract more pharmaceutical clients and generate recurring revenue. The market for pharmaceutical marketing services is substantial, with companies investing heavily in digital channels to reach healthcare professionals and patients. Univec's competitive advantage lies in its specialized focus on drug sample management.
- Developing New Safety Syringe Technologies: Univec can invest in research and development to create innovative safety syringe technologies that address unmet needs in the healthcare market. This could include syringes with improved ergonomics, enhanced safety features, or specialized applications for specific medical procedures. The market rewards innovation, and Univec can differentiate itself from competitors by offering cutting-edge products. However, this requires significant investment and technical expertise.
- Strategic Partnerships and Acquisitions: Univec can pursue strategic partnerships with larger healthcare companies or consider acquisitions to expand its product portfolio and market reach. Collaborating with established players can provide access to new distribution channels, technologies, and financial resources. Acquisitions can bring complementary products or services under Univec's umbrella, creating synergies and economies of scale. However, careful due diligence and integration planning are essential for successful partnerships and acquisitions.
- Capitalizing on Government Initiatives: Governments worldwide are increasingly focused on improving healthcare infrastructure and promoting the use of safety devices. Univec can actively participate in government tenders and initiatives to secure contracts for supplying safety syringes to public health facilities. This requires building strong relationships with government agencies and demonstrating the value proposition of Univec's products. Success in government contracts can provide a stable revenue stream and enhance Univec's reputation.
What Are UNVC's Competitive Advantages?
- Specialized product portfolio focused on safety syringes.
- Established relationships with healthcare providers and governments in specific markets.
- Proprietary online system for managing drug samples.
What Does UNVC Do?
Founded in 1992 and based in Owings Mills, Maryland, Univec, Inc. operates in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. The company's core business revolves around the production, licensing, and marketing of medical products, with a primary focus on auto-disable and safety syringes. These syringes are designed to prevent needle stick injuries and ensure safe administration of medications. Univec's product line includes 1 cc AD-syringes suitable for both aspirating and non-aspirating applications, catering to allergy, immunization, and insulin medicines. Additionally, the company manufactures sliding sheath syringes and bifurcated needle safety syringes, the latter being crucial for administering smallpox vaccines in response to potential bio-terrorist threats. Univec markets its products to private hospitals, health facilities, and distributors in the United States, as well as to governments in developing countries. Beyond manufacturing, Univec supports pharmaceutical companies by offering marketing, fulfillment, and tracking services for drug samples through an online system that connects pharmacies and managed payment providers. Despite its long history, the company currently operates with a small team of 3 employees.
What Products and Services Does UNVC Offer?
- Produces auto-disable syringes for aspirating and non-aspirating applications.
- Manufactures sliding sheath syringes designed to prevent needle stick injuries.
- Offers bifurcated needle safety syringes for administering smallpox vaccines.
- Markets syringes to private hospitals, health facilities, and distributors in the United States.
- Supplies syringes to governments of developing countries.
- Assists pharmaceutical companies with marketing, fulfillment, and tracking of drug samples.
- Provides an online system connecting pharmacies and managed payment providers for drug sample management.
How Does UNVC Make Money?
- Manufacturing and selling safety syringes to healthcare providers and governments.
- Licensing medical product technologies to other companies.
- Providing marketing and fulfillment services to pharmaceutical companies for drug samples.
What Industry Does UNVC Operate In?
Univec, Inc. operates in the drug manufacturers - specialty & generic industry, a segment characterized by intense competition and stringent regulatory requirements. The global market for specialty and generic drugs is driven by increasing healthcare expenditure and the rising prevalence of chronic diseases. Companies in this sector must navigate complex supply chains, pricing pressures, and the constant need for innovation. Univec's focus on safety syringes positions it within a niche market, but it faces competition from larger players with greater resources and broader product portfolios.
Who Are UNVC's Key Customers?
- Private hospitals and health facilities in the United States.
- Governments of developing countries.
- Pharmaceutical companies seeking marketing and fulfillment services.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
Financial Health
Univec, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Univec, Inc. stands at 6.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -24.1%, the inverse of the P/E and a quick read on earnings relative to price.
Univec, Inc. (UNVC) Valuation Context
Valued at $5.05M, UNVC is classified as a micro-cap stock.
UNVC Revenue & Earnings Trend
In Q2 FY2026, UNVC generated $21K in top-line revenue, marking a sequential increase of 9.2%. The company recorded a net loss of $311K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, UNVC averaged $0.00 in diluted EPS.
Company Profile
Univec, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Owings Mills, US. The company is led by CEO David Dalton. UNVC has traded publicly since 1997.
UNVC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized product line of safety syringes.
- Proprietary online system for drug sample management.
- Potential for growth in developing countries.
- Experience in supplying to government healthcare programs.
Bear Case
- Small market capitalization and limited financial resources.
- Negative profit margin and gross margin.
- Dependence on a limited number of products and markets.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $21,025 | -$311,471 | $0.00 |
| Q1 FY2026 | $19,250 | -$306,323 | $0.00 |
| Q4 FY2025 | $17,500 | -$284,334 | $0.00 |
| Q3 FY2025 | $33,389 | -$314,295 | $0.00 |
Q2 FY2026 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
UNVC Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
UNVC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for UNVC.
Price Targets
Wall Street price target analysis for UNVC.
UNVC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for UNVC; grades run from A+ (80-100) to F (below 30).
Leadership: David Dalton
CEO
David Dalton serves as the CEO of Univec, Inc., leading a small team of 3 employees. His leadership is crucial for navigating the company's strategic direction and operational efficiency, particularly given its limited resources and challenging financial situation.
Track Record: Assessing his track record requires further information on his tenure and the company's performance during his leadership.
UNVC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that are not eligible for OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, may not meet minimum financial standards, and carry a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires significant due diligence and an understanding of the associated risks, including potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Difficulty in obtaining accurate and reliable information about the company.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Consult with a financial advisor or investment professional.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1992.
- The company has a history of producing and marketing medical products.
- The company's products address a specific need in the healthcare market.
Common Questions About UNVC (Healthcare)
Is UNVC a good stock?
Stock Expert AI does not rate UNVC buy, sell or hold. Univec, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about UNVC stock?
As of March 17, 2026, there is no readily available analyst coverage or consensus on UNVC stock due to its OTC listing and small market capitalization.
What are the key factors to evaluate for UNVC?
Evaluate UNVC on fundamentals, analyst consensus, and risk factors. Investors should carefully consider the high-risk nature of this OTC-listed stock. Not financial advice.
How frequently does UNVC data refresh on this page?
UNVC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UNVC's recent stock price performance?
Univec, Inc. (UNVC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product line of safety syringes. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UNVC overvalued or undervalued right now?
Univec, Inc. (UNVC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of UNVC?
Yes, most major brokerages offer fractional shares of Univec, Inc. (UNVC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track UNVC's earnings and financial reports?
Univec, Inc. (UNVC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for UNVC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information is available on Univec, Inc. due to its OTC listing and small market capitalization.
- Financial data is based on available information and may not be fully comprehensive.